Genotypes for the cytochrome p450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity

European Journal of Clinical Pharmacology

Volumn 54, Issue 5, 1998, Pages 427-430

  Bathum, L ^a   Andersen Ranberg, K ^b   Boldsen, J ^b   Brosen K ^b   Jeune, B ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

CYP2D6; Longevity

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; DEBRISOQUINE 4 HYDROXYLASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DENMARK; DNA DETERMINATION; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LONGEVITY; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DNA; FEMALE; GENOTYPE; HUMANS; LONGEVITY; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES;

EID: 0031858351     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050487     Document Type: Article

References (23)

1. Wolf CR (1986) Cytochrome P-450s: polymorphic multigene families involved in carcinogen activation. Trends Genetics 2: 209-213
2. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537
3. Brøsen K, Rasmussen BB (1996) Selective serotonin re-uptake inhibitors: advances in basic research and clinical practice. Wiley. Chichester, pp 87-108
4. Ayesh SA, Idle JF, Ritchie JC, Crothers MJ, Hetzel MR (1987) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169-170
5. Zanger MU, Vilbois F, Hardwick JP, Meyer UA (1988) Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447-5454
6. Christensen PM, Gotzsche PC, Brøsen K (1997) The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 51: 389-393
7. Fleming CM, Kaisary A, Wilkinson GR, Smith P, Branch RA (1992) The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics 2: 128-134
8. Ladona MG, Abildúa RE, Ladero JM, Roman JM, Plaza MA, Agundez JA, Munoz JJ, Benitez J (1996) CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett 99: 23-28
9. Agúndez JAG, Ledesma MC, Benitez J, Ladero JM, Rodríguiez-Lescure A, Díaz-Rubio E, Diaz-Rubio M (1995) CYP2D6 genes and risk of liver cancer. Lancet 345: 830-831
10. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR (1992) Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 339: 1017-1018
11. Agúndez JAG, Jiménez-Jiménez EJ, Luengo A, Bernal ML, Molina JA, Ayuso L, Vázquez A, Parra J, Duarte J, Coria E, Ladero JM, Alvarez JC, Benitez J (1995) Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 57: 291-298
12. Madsen H, Kramer Nielsen K, Brosen K (1995): Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms a population study. Br J Clin Pharmacol 39: 433-439
13. Miller SA, Dyke DD, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215
14. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532
15. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzales FJ, Huang J, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Neben DW, Steen VM, Wolf CR, Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-201
16. Steen VM, Andreasseil OA, Daly AK, Tefre T, Borresen AL, Idle J, Gulbrandsen AK (1995) Detection of the poor metabolizer-associated CYP2D6(D) gene deletion by long-PCR technology. Pharmacogenetics 5: 215-223
17. De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Bio Chem 269: 15419-15422
18. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598
19. Bathum L, Hansen TS, Horder M, Brosen K (1997) A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles involving time resolved fluorometry. Ther Drug Monit 20: 1-6
20. Brosen K, Nielsen PN, Brusgaard K, Gram LF, Skjødt K (1994) CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 47: 221-225
21. Agúndez JAG, Rodriguez I, Olivera M, Ladero JM, Garcia MA, Ribera JM, Benitez J (1997) CYP2D6, NAT2 and CYPE1 genetic polymorphisms in nonagenarians. Age Ageing 26: 147-151
22. Schächter F, Cohen D, Kirkwood T (1993) Prospects for the genetics of human longevity. Hum Genet 91: 519-526
23. Anonymous (1996) Statistical yearbook. (in Danish) Danmarks Statistik, Copenhagen